Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

prosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma.

Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been granted fast track and orphan drug designations from the US Food and Drug Administration (FDA) in both metastatic melanoma and renal cell carcinoma.

Study Findings

The investigator-sponsored Phase 1/2 study is designed to evaluate the feasibility, safety and activity of Oncophage vaccination in patients with recurrent, high-grade glioma. The trial involves two cohorts of six patients, both receiving a minimum of four Oncophage injections: the first cohort receives biweekly vaccinations; the second cohort receives weekly vaccinations. Patients are monitored for immune response before and after Oncophage treatment using three different techniques.

According to investigators, no adverse events or toxicity identified were considered attributable to the vaccine. A tumor-specific immune response was detected after vaccination in all 12 patients. The investigators will continue to follow patients for overall survival. Researchers plan to present further results from the Phase 1/2 trial of Oncophage in late 2007 and submit the findings for peer-review publication. Based on these results, the Phase 2 portion of this study is expected to move forward in mid-2007.

"Our goal is to change the management of recurrent glioma from a life threatening disease, in which survival rates are typically 25 to 26 weeks, into a chronic disease with extended survival and improved quality of life for patients," said Dr. Parsa. "Alth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:9/15/2014)... -- Patients in today,s changing health care landscape are receiving ... setting versus a hospital. In an effort to stay ... continue to receive high quality medical care; Kaiser Permanente ... medicine residency program. The program,s progressive curriculum will prepare ... even virtual settings. "We are excited ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 /PRNewswire/ ... (Euronext Brussels:UCB) today announced results from several exploratory analyses ... women with low bone mineral density (BMD). Romosozumab is ... by inhibiting the protein sclerostin, thereby increasing bone formation ... the American Society for Bone and Mineral Research (ASBMR) ...
(Date:9/15/2014)... 2014  Catalist-listed QT Vascular Ltd. ("QT Vascular" or ... manufacturer of minimally invasive medical devices for the treatment ... Group has enrolled the first European patients in the ... patients have already been enrolled in this study with ... in Auckland, New Zealand . ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
... Calif., March 21, 2011 California-based StemCyte, Inc. announces ... cord blood banking education resource.  StemCyte offers this comprehensive ... learn about private and public cord blood banking options ... use umbilical cord blood stem cells. "StemCyte ...
... HealthCare Pharmaceuticals was handed a pounding $100 million headache ... relieve.  The law firm of Sanford Wittels & Heisler, ... Court for New Jersey, citing instances of illegal gender ... Novartis Pharmaceuticals who successfully won a jury award of ...
Cached Medicine Technology:StemCyte Launches CordBloodTV 2Bayer Gets $100M Gender Class Action Headache 2Bayer Gets $100M Gender Class Action Headache 3Bayer Gets $100M Gender Class Action Headache 4
(Date:9/15/2014)... (PRWEB) September 15, 2014 Imaging can ... for stroke who might benefit from aggressive intervention, according ... journal Radiology. , The study looked at people ... major blood vessels supplying blood to the head due ... the primary cause of up to 20 percent of ...
(Date:9/15/2014)... Ticket Down is a reputable source for ... Honeymoon Tour. Ariana Grande has quickly become an elite ... been active in the music business since 2008. In August, ... of the charts in the United States and was certified ... more than 400,000 copies. Less than a year later, she ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 College of Osteopathic ... recently sat in the lobby of Western University of Health ... Gomez. He asked Gomez about his medications, his blood pressure ... “He’s helping me a lot. He’s a good man,” Gomez ... student doctor and patient are part of the Longitudinal Chronic ...
(Date:9/15/2014)... 15, 2014 Octo Consulting Group, ... services to the federal government, today announced it ... and Atlanta, Georgia to better serve existing and ... expansion is credited to the strong growth momentum ... areas of management consulting, agile software development, data ...
(Date:9/15/2014)... 2014 - An estimated 8% of Americans will suffer ... during their lifetime. Brought on by an overwhelming or ... altered chemistry and physiology of the brain. Understanding how ... altered by PTSD is essential to developing effective interventions. ... at The University of Texas at Dallas published online ...
Breaking Medicine News(10 mins):Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4Health News:Octo Consulting Group Announces it is Opening Two New Offices in Alexandria, Virginia and Atlanta, Georgia to Better Serve Existing and Future Federal Government Clients 2Health News:EEG study findings reveal how fear is processed in the brain 2
... , SAN DIEGO and BANGALORE, India, ... ) and Biocon, Limited (NSE: BIOCON) announced today that they ... and manufacture a novel peptide therapeutic for the potential treatment ... therapeutic potential of the compound and share development costs. Research ...
... The Gerontological Society of America (GSA) invites all ... the country,s largest interdisciplinary conference in the field of ... Media representatives may register free of charge. An estimated ... the Hilton Atlanta and Atlanta Marriott Marquis ...
... , FALL RIVER, Mass., Sept. 10 ... hired two new experienced professionals to lead significant areas of ... Millstone September 1(st), will serve as Vice President of Technical ... the Memphis, TN, processing and distribution center. He joined ...
... , Gastroenterologists Applaud President,s Call for Coverage ... Gastrointestinal specialists from the American College of Gastroenterology applaud ... breast cancer exams and colonoscopy. In his health care ... President argued that "there,s no reason we shouldn,t be catching ...
... , , BOSTON, Sept. ... plans will soon enjoy a rollback of benchmark prices of ... Appeals Court last week affirmed the approval of a settlement ... a division of Wolters Kluwer Health, Inc. , , ...
... , , , ... products has long been associated with a healthy lifestyle, a new ... Nutrition provides further evidence that grapes and grape products may ... responses. The vast array of naturally occurring plant chemicals in grapes ...
Cached Medicine News:Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 2Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 3Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 4Health News:An invitation to the nation's premier aging conference 2Health News:Millstone Medical Outsourcing Enhances Company Leadership with Two New Hires 2Health News:Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 2Health News:Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 3Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 2Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 3Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 4Health News:Grapes and Grape Products Show Exciting Potential in Optimizing Health 2Health News:Grapes and Grape Products Show Exciting Potential in Optimizing Health 3
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
... for stone manipulation and removal ... wire strength permits the basket ... readily than standard flat-wire designs. ... ergonomic one-handed operation. Supplied sterile ...
Medicine Products: